Antibody-drug Conjugates Shift the Cancer Treatment Landscape: Novotech Whitepaper Examines Latest Clinical Trial Data
June 21 2024 - 5:30PM
Novotech, the global full-service clinical Contract Research
Organization (CRO) that partners with biotech companies to
accelerate the development of advanced and novel therapeutics at
every phase, has today released a key research whitepaper entitled
Antibody-drug conjugates - Global Clinical Trial Landscape.
Novotech's whitepaper examines how the antibody-drug conjugates
(ADCs), a revolutionary treatment approach, is reshaping cancer
treatment. ADCs combine the precision of monoclonal antibodies with
potent cytotoxic payloads, promising targeted drug delivery with
minimal side effects.
The report explores the evolution of ADCs, detailing key
milestones, technological advancements, clinical successes, and
highlights the significant rise in ADC research and development,
with over 150 compounds in clinical trials and 15 FDA approved
drugs. It also examines the promising commercial landscape,
showcasing the surge in investments and major pharmaceutical
companies' strategic interests in ADCs.
The Novotech research analyst team provides these expert reports
every month, completely free of charge. These reports offer
up-to-date insights into global clinical trial activity, revealing
which regions experience the highest trial volumes and the unique
factors behind these trends. They tackle the potential and real
hurdles faced by biotech firms in specific therapeutic areas and
discuss future paths in treatments and investment trends.
Examining the clinical trial activity, the report found that
from 2019 to 2023, the ADC trial landscape experienced a
substantial expansion, with close to 1,000 trials initiated
worldwide. Asia-Pacific emerged as a frontrunner, boasting a
significant Compound Annual Growth Rate (CAGR) of 42.7%,
underscoring its pivotal role in advancing research and development
in this space. North America maintained steady growth at 25.2%
CAGR, and Europe saw a moderate rise with 13.6%. The United States
and China led trial efforts, with contributions from other
countries such as Spain, Australia, and South Korea.
The report also notes a 30% increase in ADC-related publications
over the last three years, signaling growing commercial interest in
translating academic breakthroughs into tangible clinical
applications. The United States leads in both publications and
patents, followed by China, Japan, and the United Kingdom. Breast
cancer and lymphoma dominated ADC research, with growth observed in
breast cancer and myeloma studies.
Key takeaways from the report include:
- Phase II trials dominated the global ADC clinical trial
landscape, representing over 50% of all trials, followed by Phase I
and III with 27% and 22%. APAC leads in conducting trials across
all phases, with its most significant contribution in Phase
II.
- Oncology emerged as the primary therapeutic focus, with over
97% (600) of ADC trials, with Asia-Pacific leading in trial numbers
at 40%, North America at 31%, Europe and ROW contributing 18% and
11% respectively.
- A diverse landscape of targeted antigens and cytotoxic
payloads, with tubulin inhibitors emerging as the predominant
choice. The approval of trastuzumab deruxtecan (Enhertu) in 2019
highlighted a shift towards a broader range of ADC payloads,
including topoisomerase I inhibitors and STING agonists.
- With more than 340 companies actively engaged in ADC
development, including industry giants like F. Hoffmann-La Roche
and AbbVie, the landscape is witnessing a surge in interest and
investment.
- Over 200 ADCs are currently in development by companies
including Merck, Seagen, Daiichi Sankyo, AbbVie, ADC Therapeutics,
Byondis, CytomX, and ImmunoGen, signaling a shift towards targeted
cancer therapy, especially for prevalent cancers like breast and
lung cancer.
This comprehensive resource is designed as a guide for
healthcare professionals, researchers, and organizations to
accurately navigate the ADC clinical trial landscape.
Download the report here
About Novotech
Novotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical
Contract Research Organization (CRO) focused on partnering with
biotech companies to accelerate the development of advanced and
novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has
received numerous prestigious awards, including the CRO Leadership
Award 2023, the Asia Pacific Cell & Gene Therapy Clinical
Trials Excellence 2023, the Asia-Pacific Contract Research
Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including
laboratories, Phase I facilities, drug development consulting,
regulatory expertise, and has experience with over 5,000 clinical
projects, including Phase I to Phase IV clinical trials and
bioequivalence studies. With a presence in 34 office locations and
a dedicated team of 3,000+ professionals worldwide, Novotech is a
trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member
visit https://bit.ly/3RDfE4W
An infographic accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/ab1afd7f-461a-4e83-baf7-27440c30e1a5
Media Contact
David James
mediacontact@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427